术后辅助化疗联合免疫治疗在ⅢB及ⅢC期结直肠癌患者术后的应用效果分析

Analysis of the Eeffect of Postoperative Adjuvant Chemotherapy Combined with Immunotherapy in Patients with Colorectal Cancer after Stage ⅢB and ⅢC

目的:回顾性分析术后辅助化疗联合免疫治疗在ⅢB及ⅢC期结直肠癌患者术后的应用效果。方法:选取ⅢB及ⅢC期结直肠癌根治术患者235例,均接受术后辅助化疗。按是否接受免疫治疗差异分为单一辅助化疗组(n=112)和化疗联合免疫组(n=123)。对比分析两组患者术后3年无病生存期、总生存期及不良反应事件。结果:化疗联合免疫组的第1、2、3年及3年总无病生存率、病灶转移率及局部复发率均低于单一辅助化疗组(P<0.05);化疗联合免疫组患者的总生存期明显长于单一辅助化疗组(P<0.05);在化疗联合免疫组123例患者中,免疫治疗频次<4周患者的术后无病生存率(55.56%)和术后生存率(66.67%)均显著低于免疫治疗频次≥4周患者的术后无病生存率(79.10%)和术后生存率(82.61%)(P<0.05)。结论:术后辅助化疗联合免疫治疗不仅可显著降低患者治疗期间的不良反应事件发生率,而且可显著提升ⅢB及ⅢC期结直肠癌患者的3年无病生存期、总生存期。

Objective：To retrospectively analyze the effect of postoperative adjuvant chemotherapy combined with immunotherapy in colorectal cancer patients with stageⅢB andⅢC.Methods：235 patients with stageⅢB andⅢC radical resection of colorectal cancer were treated with adjuvant chemotherapy.（n=112）and chemotherapy combined immunization group（n=123） according to whether or not immunological differences were included in the single adjuvant chemotherapy group.The survival time,overall survival and adverse events of the two groups were analyzed.Results：The total disease-free survival rate,lesion metastasis rate and local recurrence rate were lower in the 1,2,3 and 3 years than those in the single adjuvant chemotherapy group（P〈0.05）.The overall survival of patients with chemotherapy combined with immunization was significantly longer than that of single adjuvant chemotherapy（P〈0.05）.The postoperative diseasefree survival rate（55.56%） and the postoperative survival rate（66.67%）were significantly higher in the 123 patients with chemotherapy combined with immunotherapy group（P〈0.05）（79.10%） and postoperative survival rate（82.61%）（P〈0.05）were significantly lower than those of immunotherapy group（P〈0.05）.Conclusion：Postoperative adjuvant chemotherapy combined with immunotherapy not only can significantly reduce the incidence of adverse events during the treatment of patients,but also can significantly improve the 3-year disease-free survival and overall survival of patients with colorectal cancer of stageⅢB andⅢC.